Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test

Infliximab is an IgG1 antitumor necrosis factor monoclonal antibody that is commonly used to treat inflammatory bowel disease (IBD) and other autoimmune disorders. However, it is known to increase the risk of reactivation of latent tuberculosis (LTBI) due to its capability to disrupt TB granulomas....

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, Anna, Giuffrè, Mauro, Crocè, Lory Saveria, Venturini, Sergio, Sablich, Renato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145928/
https://www.ncbi.nlm.nih.gov/pubmed/33946817
http://dx.doi.org/10.3390/pathogens10050535
_version_ 1783697282290417664
author Colombo, Anna
Giuffrè, Mauro
Crocè, Lory Saveria
Venturini, Sergio
Sablich, Renato
author_facet Colombo, Anna
Giuffrè, Mauro
Crocè, Lory Saveria
Venturini, Sergio
Sablich, Renato
author_sort Colombo, Anna
collection PubMed
description Infliximab is an IgG1 antitumor necrosis factor monoclonal antibody that is commonly used to treat inflammatory bowel disease (IBD) and other autoimmune disorders. However, it is known to increase the risk of reactivation of latent tuberculosis (LTBI) due to its capability to disrupt TB granulomas. We describe a case of extrapulmonary TB in a patient with ulcerative colitis who was treated with Infliximab after a negative Quantiferon Test. In addition, we report briefly on the current controversy about the appropriateness, interval, and methods for the repeated screening of latent TB in IBD patients that are treated with antitumor necrosis factor alpha (TNF-α) antibodies.
format Online
Article
Text
id pubmed-8145928
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81459282021-05-26 Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test Colombo, Anna Giuffrè, Mauro Crocè, Lory Saveria Venturini, Sergio Sablich, Renato Pathogens Case Report Infliximab is an IgG1 antitumor necrosis factor monoclonal antibody that is commonly used to treat inflammatory bowel disease (IBD) and other autoimmune disorders. However, it is known to increase the risk of reactivation of latent tuberculosis (LTBI) due to its capability to disrupt TB granulomas. We describe a case of extrapulmonary TB in a patient with ulcerative colitis who was treated with Infliximab after a negative Quantiferon Test. In addition, we report briefly on the current controversy about the appropriateness, interval, and methods for the repeated screening of latent TB in IBD patients that are treated with antitumor necrosis factor alpha (TNF-α) antibodies. MDPI 2021-04-29 /pmc/articles/PMC8145928/ /pubmed/33946817 http://dx.doi.org/10.3390/pathogens10050535 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Colombo, Anna
Giuffrè, Mauro
Crocè, Lory Saveria
Venturini, Sergio
Sablich, Renato
Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test
title Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test
title_full Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test
title_fullStr Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test
title_full_unstemmed Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test
title_short Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test
title_sort peritoneal tuberculosis during infliximab treatment in a patient with ulcerative colitis despite a negative quantiferon test
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145928/
https://www.ncbi.nlm.nih.gov/pubmed/33946817
http://dx.doi.org/10.3390/pathogens10050535
work_keys_str_mv AT colomboanna peritonealtuberculosisduringinfliximabtreatmentinapatientwithulcerativecolitisdespiteanegativequantiferontest
AT giuffremauro peritonealtuberculosisduringinfliximabtreatmentinapatientwithulcerativecolitisdespiteanegativequantiferontest
AT crocelorysaveria peritonealtuberculosisduringinfliximabtreatmentinapatientwithulcerativecolitisdespiteanegativequantiferontest
AT venturinisergio peritonealtuberculosisduringinfliximabtreatmentinapatientwithulcerativecolitisdespiteanegativequantiferontest
AT sablichrenato peritonealtuberculosisduringinfliximabtreatmentinapatientwithulcerativecolitisdespiteanegativequantiferontest

Ejemplares similares